Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Indian companies get...

    Indian companies get USFDA nod for 14 1st-time generic drugs in 2015

    Written by savita thakur thakur Published On 2016-04-16T14:16:21+05:30  |  Updated On 16 April 2016 2:16 PM IST
    Indian companies get USFDA nod for 14 1st-time generic drugs in 2015


    New Delhi : Indian pharma firms accounted for 14 of total 90 first-time generic drug approvals granted by the United States Food and Drug Administration in 2015.

    Major domestic firms such as Sun Pharma, Lupin, Glenmark, Aurobindo, Alembic and Hetero Labs figure in the list of first-time generic drug approvals released by the FDA's Office of Generic Drugs.

    The approvals include Sun Pharma's Imatinib Mesylate tablets used for treatment of cancer and Lupin's Repaglinde and Metformin Hydrochloride tablets among others.

    As per the list, Glenmark received approval for Ezetimibe tablets that are generic of lipid lowering Zetia tablets.

    In her message for the Office of Generic Drugs (OGD) Annual Report 2015, Director Kathleen Uhl said: "2015 marked the highest number of generic drug approvals and tentative approvals ever-more than 700".

    OGD's review processes to expedite thorough review of pending abbreviated new drug applications (ANDAs) and cutting the average review time is being streamlined, she added.

    "Generic drugs make up nearly 88 per cent of prescriptions filled in the United States and represent affordable access to treatment for many patients and consumers," Uhl said.

    However, in 2015 many Indian pharma firms also came under the scanner of the regulator in the US, which remains a key market for Indian generic drug makers.

    Major firms such as Sun Pharma, Dr Reddy's Laboratories and Wockhardt faced regulatory issues during 2015.


    Abbreviated New Drug ApplicationANDAAurobindocancerDr Reddygeneric drugsGlenmarkLupinMetformin Hydrochloride tabletsOffice of Generic DrugsOGDSun PharmaUS Food and Drug AdministrationUSFDAWockhardt
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok